$UMH

UMH PROPERTIES, INC. SECOND QUARTER 2026 OPERATIONS UPDATE

UMH Properties (NYSE: UMH) reported preliminary Q2 2026 operating updates: total rental and related income rose 10.3% and same-store rose 9.2% vs. July 2025; home sales income rose 9.2% to $11.4M from $10.5M. It rented 193 new homes; occupancy was 95.3% (11,200 rentals). UMH sold ~353k Series D preferred shares at $21.61 for $7.6M and amended its $260M revolver (up to $600M).

Original reporting
Published Jul 2, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UMH PROPERTIES, INC. SECOND QUARTER 2026 OPERATIONS UPDATE — source image
Decision brief

The 30-second read

$UMHBullishMed
01

Why it matters

Operating metrics (rental income growth, occupancy, and home sales) plus financing actions (preferred ATM proceeds and revolver amendment with lower interest) provide a near-term catalyst for sentiment and positioning into the final earnings release.

02

Market read

Traders can reassess UMH’s near-term fundamentals and funding cost trajectory into the Aug. 5 final Q2 print based on the disclosed operating and credit-facility changes.

03

What to watch

The preferred ATM issuance increases equity funding but can affect capital structure and future dividend/financing optics; the revolver’s unencumbered-capitalization-rate change may also signal underwriting assumptions.

Relevance 7/10Novelty 7/10Timing: Ahead of the company’s final Q2 results on Aug. 5, 2026 (after the close).

Background

UMH is a manufactured-home REIT; this is a Q2 2026 operations update ahead of its scheduled Aug. 5 final results.

Company-level read

Ticker impact

$UMHBullishMedium confidence
Context

UMH reports Q2 operating momentum plus a new preferred ATM issuance and an amended revolver with lower interest and updated borrowing capacity.

Expected impact

Likely supportive for the stock versus peers on improved occupancy/sales and reduced borrowing costs, though magnitude depends on how investors weigh preliminary vs final Q2 results.

Evidence & confidence

The article discloses multiple concrete datapoints (income growth, occupancy, preferred ATM proceeds, revolver capacity and rate reduction) but does not provide guidance or a final earnings print; it also flags figures as preliminary estimates.

Market effects

Manufactured-home REIT peers may see read-across on demand/occupancy strength and on how lenders are pricing revolver credit lines.

Limited direct regional spillover; the update is company-specific across multiple states.

Low; this is a US REIT funding/operations update with no cross-border catalyst.

Counterpoint

Investors may discount the update because it is explicitly preliminary and lacks full Q2 financial statements or explicit forward guidance.

Key entities

  • UMH Properties, Inc.

    Manufactured-home REIT providing Q2 2026 operating and financing update, including preferred ATM issuance and revolver amendment.

  • Series D Preferred stock (ATM program)

    UMH issued and sold ~353,000 shares at a weighted average price of $21.61, raising gross proceeds of ~$7.6M.

  • Unsecured revolving line of credit

    Amended/extended revolver with $260M available borrowings, $340M accordion (up to $600M), and ~35–40 bps interest reduction depending on leverage.

Related articles

$UMHMedAI 8/10

UMH (UMH) Q2 2026 Earnings Call Transcript

UMH Properties (UMH) reported Q2 2026 normalized FFO per share of $0.25, up 9% from $0.23, and total income of $71.6 million, up 7%. Rental and related income rose to $61.1 million, and home sales revenue hit $11.5 million. Full-year normalized FFO guidance was reiterated at $0.98 to $1.04. Debt was $789 million; occupancy was 89%.

$UMHMed

UMH PROPERTIES, INC. REPORTS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026

UMH PROPERTIES, INC. (UMH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 UMH PROPERTIES, INC. Juniper Business Plaza 3499 Route 9 North, Suite 3-C Freehold, NJ 07728 (732) 577-9997 Fax: (732) 577-9980 FOR IMMEDIATE RELEASE August 5, 2026 Contact: Nelli Madden 732-577-9997 UMH PROPERTIES, INC. REPORTS RESULTS FOR THE SECOND QUARTER ENDED J

$MGNXMedAI 8/10

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Other Events. MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN • Durable responses observed across multiple tumor types during dose escalation • MGC026 demonstrated 27% best overall response rate (6/22 pati

$AVBPMedAI 8/10

First human data on an experimental cancer drug will be presented in a late-breaking session.

ArriVent BioPharma (Nasdaq: AVBP) announced that initial safety and efficacy data from its Phase 1 study of ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, will be presented at ESMO Congress 2026. The company will host a webinar on October 26, 2026, to discuss the data. ARR-217 is ArriVent's lead clinical candidate, obtained via a collaboration with Lepu Biopharma.

$MMMHigh

Post-it Notes maker 3M eyes AI gold rush in major Amazon deal

3M (MMM) expanded its deal with Amazon (AMZN) for up to $6B in fiber-optic gear for AI/data centers. 3M shares rose 5% post-announcement. Amazon gets a warrant to buy 3.16M 3M shares at $164.89 each, tied to purchase milestones. 3M also invested in Genius Electronic Optical to scale production. Microsoft (MSFT) is another key partner.

$ZYMEHighAI 8/10

Jefferies raises Zymeworks stock price target on Roche deal

Jefferies raised its price target on Zymeworks (NASDAQ:ZYME) to $52 from $50, maintaining a Buy rating after its licensing deal with Roche. The deal includes $55M upfront, $40M upon Phase 1b trial initiation, and up to $718M in milestone payments. Zymeworks' stock is currently at $28.30, up 63% over the past year. The company also completed its acquisition of Theravance Biopharma, which could generate over $100M in annual cash flow.